findmyKOL
Clinical trialNCT02792114Active, not recruitingPhase 1Interventional

T-Cell Therapy for Advanced Breast Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment186Breast CancerMetastatic HER2-negative Breast
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering Cancer Center (consent and Follow-Up Only)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth (consent and Follow-Up Only)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (consent and Follow-Up Only)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center at Commack (consent and Follow-Up Only)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (consent and Follow-Up Only)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Memorial Sloan Kettering Nassau (consent and Follow-Up Only)

    Uniondale, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

RimiducidCyclophosphamide →Mesothelin-targeted T cells
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jun 2016
Primary completion
30 Jun 2027
Completion
30 Jun 2027
Last update posted
16 Jul 2026
Registered enrollment
186
Registry id
NCT02792114
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.